LS
JAZZ icon

Livforsakringsbolaget Skandia’s Jazz Pharmaceuticals JAZZ Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,180
Closed -$3.23M – 668
2018
Q3 		$3.23M Sell
19,180
-4,100
-18% -$705K 0.38% 72
2018
Q2 		$4.01M Hold
23,280
– – 0.36% 74
2018
Q1 		$3.52M Hold
23,280
– – 0.34% 83
2017
Q4 		$3.13M Sell
23,280
-1,700
-7% -$236K 0.3% 93
2017
Q3 		$3.65M Sell
24,980
-845
-3% -$128K 0.33% 80
2017
Q2 		$4.02M Hold
25,825
– – 0.37% 70
2017
Q1 		$3.75M Sell
25,825
-3,300
-11% -$430K 0.35% 72
2016
Q4 		$3.18K Sell
29,125
-245,867
-89% -$27.4M 0.16% 133
2016
Q3 		$18.5M Buy
274,992
+245,112
+820% +$33M 0.91% 13
2016
Q2 		$4.22M Buy
29,880
+1,400
+5% +$206K 0.19% 114
2016
Q1 		$3.72M Buy
28,480
+4,100
+17% +$510K 0.17% 132
2015
Q4 		$3.43M Buy
24,380
+14,200
+139% +$1.97M 0.16% 137
2015
Q3 		$1.35M Buy
10,180
+1,830
+22% +$315K 0.07% 324
2015
Q2 		$1.47M Buy
8,350
+1,600
+24% +$287K 0.07% 331
2015
Q1 		$1.17M Buy
+6,750
New +$1.16M 0.06% 410

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Livforsakringsbolaget Skandia's JAZZ Position: Q4 2018 in Review

Livforsakringsbolaget Skandia sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 19,180 shares — an estimated $3.23M sold.

Livforsakringsbolaget Skandia first reported a position in JAZZ in Q1 2015 and held it in 15 quarters. The position peaked at $18.5M in Q3 2016. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

  • Livforsakringsbolaget Skandia reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Livforsakringsbolaget Skandia sold 19,180 Jazz Pharmaceuticals shares in Q4 2018, an estimated $3.23M.
  • Livforsakringsbolaget Skandia first reported a position in Jazz Pharmaceuticals in Q1 2015 and held it in 15 quarters.
  • Livforsakringsbolaget Skandia's Jazz Pharmaceuticals position peaked at $18.5M in Q3 2016.
  • 417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Livforsakringsbolaget Skandia's 13F filing for Q4 2018, filed 6 Feb 2019.